Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dachau – page 14

1 447 clinical trials in Dachau, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dachau at a glance
1 447
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 447 trials in Dachau

Open in trial search

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY4395089
  • Sponsor:Eli Lilly & Co.

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verastem Inc.

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Short‑course sublingual ITULAZAX birch pollen extract with Lactobacillus rhamnosus GG for patients with pollen‑associated food allergy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Betula verrucosa (108)
  • Sponsor:Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MK-1045
  • Sponsor:Merck Sharp & Dohme LLC

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dachau

What the registry says about research in the country

01 Respiratory Medicine

Research focusing on respiratory syncytial virus (RSV) and chronic obstructive pulmonary disease, evaluating innovative treatment approaches and preventive measures.

  • RSV vaccination studies in older adults
  • COPD treatment optimization
  • Respiratory therapy combinations

Advanced trials investigating both preventive vaccines and therapeutic interventions for respiratory conditions.

02 Gastroenterology

Comprehensive studies addressing inflammatory bowel diseases, including breakthrough treatments for ulcerative colitis and Crohn's disease.

  • Novel therapeutic approaches for UC
  • Crohn's disease management
  • Combination therapy investigations

Multiple innovative treatments being evaluated to improve patient outcomes in inflammatory bowel conditions.

03 Cardiovascular Medicine

Critical research in atrial fibrillation and related cardiovascular conditions, exploring new therapeutic strategies and prevention methods.

  • Cardioembolic event prevention
  • Acute coronary syndrome management
  • Anticoagulation therapy optimization

Innovative approaches to cardiac care and stroke prevention in high-risk patients.

04 Hematology

Advanced research in chronic lymphocytic leukemia, particularly focusing on high-risk patients with specific genetic markers.

  • Triple combination therapy evaluation
  • Treatment of high-risk CLL
  • Novel therapeutic approaches

Cutting-edge treatments targeting specific genetic mutations in blood disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.